Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
USA

Credit Suisse Continues to Exceed Recommendations from Charles River Laboratories International (CRL)

Fintel reports that on May 12, 2023, Credit Suisse maintained Charles River Laboratories International (NYSE:CRL) coverage excellent recommendation.

Analyst Price Expectations Suggest a 30.96% Gain

One-year average as of May 11, 2023 target price 256.36 for Charles River Laboratories International. Expectations range from lows of $205.03 to highs of $304.50. The average price target is up 30.96% from the most recently reported closing price of 195.75.

see our corporate leaderboard The target price has the most upside potential.

Charles River Laboratories International’s annual revenue is expected to increase 2.36% to 4,188 million.Non-GAAP Annual Forecast EPS It’s 11.55.

What is Fund Sentiment?

there is 1,323 foundations or institutions reporting positions At Charles River Laboratories International. That’s an increase of 34 owners or 2.64% over the last quarter.Portfolio average weight out of all funds CRL only was 0.31%, an increase of 15.38%. Total shares owned by institutional investors fell by 0.64% to 57,362,000 shares in the last three months. of put/call ratio The CRL is at 1.58, indicating a bearish outlook.

What are other shareholders doing?

Stocks held by CRL / Charles River Laboratories International Inc. Institution

Price T Row Associates owns 1,853,000 shares, representing 3.63% of the company. Earlier filings reported that the company owned 1,586,000 shares. will increase 14.36%.office increased Portfolio allocation in CRL increased 26.95% quarter-on-quarter.

Kane Anderson Rudnick Investment Management holds 1,617,000 shares representing 3.17% of the company’s ownership. Earlier filings reported that the company owned 1,632,000 shares. Decrease 0.96%.office increased The portfolio’s allocation to CRL increased 3.13% quarter-on-quarter.

VTSMX – Vanguard Total Stock Market Index Fund Investor Stocks owns 1,546,000 shares, representing 3.03% of the company. Earlier filings reported that the company owned 1,514,000 shares. will increase 2.08%.office increased The portfolio’s allocation to CRL increased 4.42% quarter-on-quarter.

Clearbridge Investments owns 1,407,000 shares, representing 2.76% of the company. Earlier filings reported that the company owned 1,371,000 shares. will increase 2.57%.office Diminished The portfolio’s allocation to CRL increased by 8.03% quarter-on-quarter.

VFINX – Vanguard 500 Index Fund Investor Stock owns 1,176,000 shares, representing 2.31% of the company. Earlier filings reported that the company owned 1,153,000 shares. will increase 1.96%.office increased The portfolio’s allocation to CRL increased 4.05% quarter-on-quarter.

Background information from Charles River Laboratories International
(This description was provided by us.)

Charles River provides essential products and services that enable pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the world to accelerate their research and drug development efforts. Our dedicated employees are focused on delivering exactly what is needed to improve and accelerate new therapeutic discovery, early stage development and safe manufacturing for patients in need. is placed.

View All Charles River Laboratories International Notification to Regulatory Authorities.

This story was originally Fintel.

The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.

Summarize this content to 100 words

Fintel reports that on May 12, 2023, Credit Suisse maintained Charles River Laboratories International (NYSE:CRL) coverage excellent recommendation. Analyst Price Expectations Suggest a 30.96% Gain One-year average as of May 11, 2023 target price 256.36 for Charles River Laboratories International. Expectations range from lows of $205.03 to highs of $304.50. The average price target is up 30.96% from the most recently reported closing price of 195.75.

see our corporate leaderboard The target price has the most upside potential. Charles River Laboratories International’s annual revenue is expected to increase 2.36% to 4,188 million.Non-GAAP Annual Forecast EPS It’s 11.55. What is Fund Sentiment? there is 1,323 foundations or institutions reporting positions At Charles River Laboratories International. That’s an increase of 34 owners or 2.64% over the last quarter.Portfolio average weight out of all funds CRL only was 0.31%, an increase of 15.38%. Total shares owned by institutional investors fell by 0.64% to 57,362,000 shares in the last three months. of put/call ratio The CRL is at 1.58, indicating a bearish outlook. What are other shareholders doing? Price T Row Associates owns 1,853,000 shares, representing 3.63% of the company. Earlier filings reported that the company owned 1,586,000 shares. will increase 14.36%.office increased Portfolio allocation in CRL increased 26.95% quarter-on-quarter. Kane Anderson Rudnick Investment Management holds 1,617,000 shares representing 3.17% of the company’s ownership. Earlier filings reported that the company owned 1,632,000 shares. Decrease 0.96%.office increased The portfolio’s allocation to CRL increased 3.13% quarter-on-quarter.

VTSMX – Vanguard Total Stock Market Index Fund Investor Stocks owns 1,546,000 shares, representing 3.03% of the company. Earlier filings reported that the company owned 1,514,000 shares. will increase 2.08%.office increased The portfolio’s allocation to CRL increased 4.42% quarter-on-quarter. Clearbridge Investments owns 1,407,000 shares, representing 2.76% of the company. Earlier filings reported that the company owned 1,371,000 shares. will increase 2.57%.office Diminished The portfolio’s allocation to CRL increased by 8.03% quarter-on-quarter. VFINX – Vanguard 500 Index Fund Investor Stock owns 1,176,000 shares, representing 2.31% of the company. Earlier filings reported that the company owned 1,153,000 shares. will increase 1.96%.office increased The portfolio’s allocation to CRL increased 4.05% quarter-on-quarter. Background information from Charles River Laboratories International(This description was provided by us.)
Charles River provides essential products and services that enable pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the world to accelerate their research and drug development efforts. Our dedicated employees are focused on delivering exactly what is needed to improve and accelerate new therapeutic discovery, early stage development and safe manufacturing for patients in need. is placed.

View All Charles River Laboratories International Notification to Regulatory Authorities. This story was originally Fintel.

The views and opinions expressed herein are those of the authors and do not necessarily reflect those of Nasdaq, Inc.

https://www.nasdaq.com/articles/credit-suisse-maintains-charles-river-laboratories-international-crl-outperform Credit Suisse Continues to Exceed Recommendations from Charles River Laboratories International (CRL)

Back to top button